Lyon: Fosun Pharma (02196.HK) employee stock ownership plan increases growth visibility, target price raised to 29.6 Hong Kong dollars.

Zhixin Financial APP learned that, according to a report released by Lyon, Fosun Pharma (02196.HK) showed resilience in its second quarter performance, with a 7.2% increase in revenue and a 22.5% increase in net profit from the previous quarter, mainly driven by strong sales of innovative products. The bank believes that the new Employee Stock Ownership Plan (ESOP) provides greater visibility for its growth and partially alleviates market concerns following leadership changes. The bank has raised its core profit forecast for Fosun Pharma from this year to 2027 by about 13% to 21%, raising the H-share target price from 15.6 Hong Kong dollars to 29.6 Hong Kong dollars, and maintaining an outperform rating.